Cancer Immunotherapy
"Outpatient Chemoimmunotherapy for Patents with Metastatic Melanoma."
Published in Cancer Weekly, October 19th, 1998
According to an abstract submitted by the author to the 8th International Congress on Infectious Diseases, held May 15-18, 1998, in Boston, Massachusetts, "Aggressive inpatient protocols of chemoimmunotherapy for metastatic melanoma have yielded encouraging response rates but have required lengthy hospitalizations. To reduce or eliminate the need for hospitalization, we developed an outpatient regimen of chemoimmunotherapy, and assessed its response rate and toxicity. Eligible patients with measurable metastatic melanoma received BCNIJ 150 mg/m2, DTIC 660 mg/m2, and cisplatin 75 mg/m2 in an infusion center every 3 to 4 weeks (BCNU every 6-8 weeks) with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (1998-10-19)
More Articles from Cancer Weekly
- Cancer Gene Therapy
Connexin 43 Affects Suicide Gene Therapy Bystander Effect - Cancer Gene Therapy
Phenotypic Knock-Out of EBV LMP1 Opens the Door for Several Anticancer Strategies - Cancer Immunotherapy
Gene-Mediated Suppression of TGF-(beta) Synthesis Inhibits Gliomas In Vivo - Apheresis
Cell Yields are Lower in Second Procedure - Bone Marrow Transplantation
Marrow Karyotype Has Pivotal Role in Predicting Outcome - Hematopoiesis
Extensive Clinical Use of G-CSF May Be Damaging - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
